Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Normally, nerve fibers carry electrical impulses through the spinal cord, providing communication between the brain and the arms and legs. In people with spinal cord injury, some fibers may be destroyed at the site of injury, while others remain connected but do not work correctly to carry electrical impulses. As a result, subjects with an incomplete spinal cord injury may have spasticity which is muscle spasms or muscle stiffness that makes movement difficult. Fampridine-SR is an experimental drug that increases the ability of the nerve to conduct electrical impulses. This study will examine the effects of Fampridine-SR on moderate to severe lower-limb spasticity, as well as the effects on bodily functions such as bladder control, bowel function and sexual function. The study will also examine the possible risks of taking Fampridine-SR.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| fampridine-SR 50mg/day | Active Comparator |
| |
| Placebo | Placebo Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Fampridine-SR | Drug | 25mg bid (twice daily) |
| |
| Placebo |
| Measure | Description | Time Frame |
|---|---|---|
| Double-blind Change From Baseline in Ashworth Score Evaluating Spasticity | The Ashworth evaluates the functioning of two lower extremity muscle groups, the hamstring and quadriceps muscles, while in the supine position. The test measures extension of the right and left hamstring muscle and flexion of the right and left quadriceps muscle using the following 5-point grading scale: 1=no increased tone; 2=slight increase in tone, giving a "catch" when the affected part is moved in flexion or extension; 3=more marked increase in tone, but affected part is easily flexed; 4=considerable increase in tone, passive movement is difficult; 5=affected part is rigid in flexion and extension. The Ashworth Score was determined by adding all individual scores for each muscle group and dividing by four. Higher Ashworth Scores indicated greater spasticity. | Baseline (visits 2,3) average score days 7,14 and double-blind treatment period (visits 4-7) average score days 28-98 |
| Double-blind Change From Baseline in Mean Subject's Global Impression (SGI) Scores | The SGI is a 7-unit ordinal scale used by the subject to evaluate the effects of study medication on his/her quality of life during the preceding week, with higher scores denoting greater satisfaction. A positive change score in SGI signifies improved outcome. The questionnaire consisted of one question (How do you feel about the effects of the investigational drug over the past 7 days?). The answer was based on a numerical rating scale where 1=terrible; 2=unhappy; 3=mostly dissatisfied; 4=neutral/mixed; 5=mostly satisfied; 6=pleased; 7=delighted. | Baseline (visits 2,3) average score days 7,14 and double-blind treatment period (visits 4-7) average score days 28-98 |
| Measure | Description | Time Frame |
|---|---|---|
| Double-blind Change From Baseline in Mean Spasm Frequency/Severity Scores | The Spasm Frequency score is the average rating by the clinician of the left and right arm(s) and leg(s), each evaluated on a 4-point scale (from 0=no spasms to 4=spontaneous spasms occurring more than ten times per hour), with higher scores denoting a greater degree of muscle spasms. The Spasm Severity score is the average rating of the left and right arm(s) and leg(s), each evaluated on a three-point scale (mild, moderate, or severe) as rated by the clinician on the basis of patient self-report. On both, a negative change in score signifies improvement in muscle spasms. The average Spasm Frequency/Spasm Severity Score was calculated as the average of the left and right non-missing scores. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Andrew Blight, MD | Acorda Therapeutics | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| UAB School of Medicine, 190 Spain Rehab Center | Birmingham | Alabama | 35233 | United States | ||
| Long Beach VA Medical Center |
Not provided
| Label | URL |
|---|---|
| Related Info | View source |
Not provided
Investigational drug assignments were communicated through an Interactive Voice Response System (IVRS).
The randomization schedule was created prior to the start of the study, and was blocked and stratified by site and by concomitant anti-spasmodic medication status to ensure treatment balance between patients who were treated with anti-spasmodic medications upon entry into the study and those who were not.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Fampridine-SR 50mg/Day | Fampridine-SR : 25mg bid (twice daily) |
| FG001 | Placebo | Placebo : Placebo |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Drug |
Placebo |
|
| Baseline (visits 2,3) average score days 7,14 and double-blind treatment period (visits 4-7) average score days 28-98 |
| Double-blind Change From Baseline in Mean Clinician's Global Impression (CGI) Scores | The supervising clinician rated the patient's neurological condition following treatment as compared to the screening visit on a seven-point scale (from 1=very much improved to 7=very much worse). The assessment was based on the clinician's overall impression of the patient's neurological status (specifically bowel, bladder, and sexual function; spasticity; and other neurological functions) and general state of health related to his or her participation in the study. Negative change scores indicated a change for the better. | Baseline (visits 2,3) average of days 7-14 and double-blind treatment period (visits 4-7) average of days 28-98) |
| Stable-dose Change From Baseline in Mean American Spinal Injury Association(ASIA) Total Motor Score | Ten key muscle groups for the right and left sides were rated on a 0 (absent) to 5 (normal) scale, with a possible total score of 100. Higher positive change scores indicate improved motor function. | Baseline (visits 2,3) average score days 7,14 and stable-dose treatment period (visits 5-7) average score days 56-98 |
| Change From Baseline in Mean International Index of Erectile Function (IIEF) Score | Male patients were asked to complete the IIEF questionnaire on sexual function. The IIEF is a brief, reliable, and valid self-administered questionnaire of 15 questions (items) that were categorized into five domains: Erectile Function (EF) scores: 0-6 Severe dysfunction, 7-12 Moderate dysfunction, 13-18 Mild to moderate dysfunction, 19-24 Mild dysfunction, 25-30 No dysfunction. Orgasmic Function (OF) score range: 0-2 Severe dysfunction to 9-10 No dysfunction, Sexual Desire (SD) score range: 0-2 Severe dysfunction to 9-10 No dysfunction, Intercourse Satisfaction (IS) score range: 0-3 Severe dysfunction to 13-15 No dysfunction, and Overall Satisfaction (OS) score range: 0-2 Severe dysfunction to 9-10 No dysfunction. Domain scores were derived by summing the individual items within a given domain. Final scale ranges from 0 (negative) to 5 (positive). A positive change in IIEF domain scores signifies improvement. | Baseline (visit 1) average score obtained at day 1 and stable treatment period (visit 7) average score day 98 |
| Change From Baseline in Mean Female Sexual Function Index (FSFI) Scores | The FSFI is a brief, reliable, and valid self-administered questionnaire of 19 questions (items). It contains six domains: Desire (2 items score range: 1 Very low or none at all to 5 Very high), Arousal (4 items score range: 0 No sexual activity to 5 Almost always or always), Lubrication (4 items score range: 0 No sexual activity to 5 Almost always or always), Orgasm (3 items score range: 0 No sexual activity to 5 Almost always or always), Satisfaction (3 items score range: 0 No sexual activity to 5 Very satisfied) and Pain (3 items score range: 0 Did not attempt intercourse to 5 Almost never or never). A positive change signifies improvement. | Baseline (visit 1) average score obtained at day 1 and stable treatment period (visits 4-7) average score days 28-98 |
| Adjusted Mean Change in Subject Bladder/Bowel Function Diary Scores | Bowel/bladder questions pertaining to the average number of times per day the patient experienced accidental urination/leakage and the average number of bowel movements per day were asked of all patients daily. A negative change in patient bladder/bowel function diary score signifies improvement. | Baseline (visit 1) average score obtained at day 1 and double-blind treatment period (visits 4-7) average score days 28-98 |
| Adjusted Mean Change in Subject Bowel Function Diary Scores | Bowel questions pertaining to the average number of minutes per day spent on bowel routine were asked of all patients daily. A negative change in patient bowel function diary score signifies improvement. | Baseline (visit 1) average score obtained at day 1 and double-blind treatment period (visits 4-7) average score days 28-98 |
| Long Beach |
| California |
| 90822 |
| United States |
| University of California, Davis | Sacramento | California | 95817 | United States |
| Santa Clara Valley Medical Center | San Jose | California | 95128 | United States |
| Craig Hospital | Englewood | Colorado | 80110 | United States |
| Hospital for Special Care | New Britain | Connecticut | 06503 | United States |
| Hines VA Hospital | Hines | Illinois | 60141 | United States |
| Boston University Medical Center | Boston | Massachusetts | 02118 | United States |
| University of Michigan | Ann Arbor | Michigan | 48109 | United States |
| Rehabilitation Institute of Michigan | Detroit | Michigan | 48201 | United States |
| Minneapolis VA Hospital | Minneapolis | Minnesota | 55417 | United States |
| University of Missouri | Columbia | Missouri | 65212 | United States |
| St. Louis University | St Louis | Missouri | 63104 | United States |
| University of Rochester/Strong Memorial Hospital | Rochester | New York | 14642 | United States |
| SUNY Upstate Clinical Trials Office | Syracuse | New York | 13045 | United States |
| Helen Hayes Hospital | West Haverstraw | New York | 13045 | United States |
| Charlotte Institute of Rehabilitation | Charlotte | North Carolina | 28203 | United States |
| Coastal AHEC | Wilmington | North Carolina | 28402 | United States |
| Ohio State University | Columbus | Ohio | 43210 | United States |
| Miami Valley Hospital- Rehabilitation Institute of Medicine | Dayton | Ohio | 45409 | United States |
| Thomas Jefferson University Hospital | Philadelphia | Pennsylvania | 19107 | United States |
| VA North Texas Health Care System | Dallas | Texas | 75216 | United States |
| Southwestern Medical Center at Dallas | Dallas | Texas | 75390 | United States |
| INOVA Institute of Research and Education | Falls Church | Virginia | 22042 | United States |
| Medical College of Virginia/VCU | Richmond | Virginia | 23298 | United States |
| University of Washington Medical Center, Dept. of Rehabilitation | Seattle | Washington | 98195 | United States |
| Wood VA Medical Center | Milwaukee | Wisconsin | 53295 | United States |
| Health Sciences Centre | Winnipeg | Manitoba | R3A 1M4 | Canada |
| Chedoke-McMaster Hospital | Hamilton | Ontario | L8N 3Z5 | Canada |
| St. Mary's of the Lake Hospital | Kingston | Ontario | K7L 5A2 | Canada |
| Intent to Treat (ITT) Population |
|
| Safety Population |
|
| Efficacy Population |
|
| COMPLETED |
|
| NOT COMPLETED |
|
|
104 patients randomized to Fampridine-SR 50mg/day 100 patients randomized to Placebo. Total patients randomized = 204.
Overall, 203 (99.5%) patients were included in the ITT population, 182 (89.2%) in the Efficacy population and 203 (99.5%) in the Safety population.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Fampridine-SR 50mg/Day | Fampridine-SR : 25mg bid (twice daily) |
| BG001 | Placebo | Placebo : Placebo |
| BG002 | Total | Total of all reporting groups |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean | Standard Deviation | Years |
| |||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| ||||||||||||||||
| Race/Ethnicity, Customized | Number | participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Double-blind Change From Baseline in Ashworth Score Evaluating Spasticity | The Ashworth evaluates the functioning of two lower extremity muscle groups, the hamstring and quadriceps muscles, while in the supine position. The test measures extension of the right and left hamstring muscle and flexion of the right and left quadriceps muscle using the following 5-point grading scale: 1=no increased tone; 2=slight increase in tone, giving a "catch" when the affected part is moved in flexion or extension; 3=more marked increase in tone, but affected part is easily flexed; 4=considerable increase in tone, passive movement is difficult; 5=affected part is rigid in flexion and extension. The Ashworth Score was determined by adding all individual scores for each muscle group and dividing by four. Higher Ashworth Scores indicated greater spasticity. | Intent to Treat (ITT) Population. Number of participants analyzed is number of patients with available data at both baseline and double-blind treatment period. | Posted | Mean | Standard Error | units on a scale | Baseline (visits 2,3) average score days 7,14 and double-blind treatment period (visits 4-7) average score days 28-98 |
|
|
| ||||||||||||||||||||||||||||
| Primary | Double-blind Change From Baseline in Mean Subject's Global Impression (SGI) Scores | The SGI is a 7-unit ordinal scale used by the subject to evaluate the effects of study medication on his/her quality of life during the preceding week, with higher scores denoting greater satisfaction. A positive change score in SGI signifies improved outcome. The questionnaire consisted of one question (How do you feel about the effects of the investigational drug over the past 7 days?). The answer was based on a numerical rating scale where 1=terrible; 2=unhappy; 3=mostly dissatisfied; 4=neutral/mixed; 5=mostly satisfied; 6=pleased; 7=delighted. | ITT population. Number of participants analyzed is number of patients with available data at both baseline and double-blind treatment period. | Posted | Mean | Standard Error | units on a scale | Baseline (visits 2,3) average score days 7,14 and double-blind treatment period (visits 4-7) average score days 28-98 |
|
| |||||||||||||||||||||||||||||
| Secondary | Double-blind Change From Baseline in Mean Spasm Frequency/Severity Scores | The Spasm Frequency score is the average rating by the clinician of the left and right arm(s) and leg(s), each evaluated on a 4-point scale (from 0=no spasms to 4=spontaneous spasms occurring more than ten times per hour), with higher scores denoting a greater degree of muscle spasms. The Spasm Severity score is the average rating of the left and right arm(s) and leg(s), each evaluated on a three-point scale (mild, moderate, or severe) as rated by the clinician on the basis of patient self-report. On both, a negative change in score signifies improvement in muscle spasms. The average Spasm Frequency/Spasm Severity Score was calculated as the average of the left and right non-missing scores. | ITT Population. Number of participants analyzed is number of patients with available data at both baseline and double-blind treatment period. | Posted | Mean | Standard Error | units on a scale | Baseline (visits 2,3) average score days 7,14 and double-blind treatment period (visits 4-7) average score days 28-98 |
| ||||||||||||||||||||||||||||||
| Secondary | Double-blind Change From Baseline in Mean Clinician's Global Impression (CGI) Scores | The supervising clinician rated the patient's neurological condition following treatment as compared to the screening visit on a seven-point scale (from 1=very much improved to 7=very much worse). The assessment was based on the clinician's overall impression of the patient's neurological status (specifically bowel, bladder, and sexual function; spasticity; and other neurological functions) and general state of health related to his or her participation in the study. Negative change scores indicated a change for the better. | ITT Population. Number of participants analyzed is number of patients with available data at both baseline and double-blind treatment period. | Posted | Mean | Standard Error | units on a scale | Baseline (visits 2,3) average of days 7-14 and double-blind treatment period (visits 4-7) average of days 28-98) |
|
| |||||||||||||||||||||||||||||
| Secondary | Stable-dose Change From Baseline in Mean American Spinal Injury Association(ASIA) Total Motor Score | Ten key muscle groups for the right and left sides were rated on a 0 (absent) to 5 (normal) scale, with a possible total score of 100. Higher positive change scores indicate improved motor function. | ITT Population. Number of participants analyzed is number of patients with available data at both baseline and stable-blind treatment period. | Posted | Mean | Standard Error | units on a scale | Baseline (visits 2,3) average score days 7,14 and stable-dose treatment period (visits 5-7) average score days 56-98 |
|
| |||||||||||||||||||||||||||||
| Secondary | Change From Baseline in Mean International Index of Erectile Function (IIEF) Score | Male patients were asked to complete the IIEF questionnaire on sexual function. The IIEF is a brief, reliable, and valid self-administered questionnaire of 15 questions (items) that were categorized into five domains: Erectile Function (EF) scores: 0-6 Severe dysfunction, 7-12 Moderate dysfunction, 13-18 Mild to moderate dysfunction, 19-24 Mild dysfunction, 25-30 No dysfunction. Orgasmic Function (OF) score range: 0-2 Severe dysfunction to 9-10 No dysfunction, Sexual Desire (SD) score range: 0-2 Severe dysfunction to 9-10 No dysfunction, Intercourse Satisfaction (IS) score range: 0-3 Severe dysfunction to 13-15 No dysfunction, and Overall Satisfaction (OS) score range: 0-2 Severe dysfunction to 9-10 No dysfunction. Domain scores were derived by summing the individual items within a given domain. Final scale ranges from 0 (negative) to 5 (positive). A positive change in IIEF domain scores signifies improvement. | ITT Population. N = number of participants analyzed with available data at both baseline and stable treatment period. | Posted | Mean | Standard Error | units on a scale | Baseline (visit 1) average score obtained at day 1 and stable treatment period (visit 7) average score day 98 |
| ||||||||||||||||||||||||||||||
| Secondary | Change From Baseline in Mean Female Sexual Function Index (FSFI) Scores | The FSFI is a brief, reliable, and valid self-administered questionnaire of 19 questions (items). It contains six domains: Desire (2 items score range: 1 Very low or none at all to 5 Very high), Arousal (4 items score range: 0 No sexual activity to 5 Almost always or always), Lubrication (4 items score range: 0 No sexual activity to 5 Almost always or always), Orgasm (3 items score range: 0 No sexual activity to 5 Almost always or always), Satisfaction (3 items score range: 0 No sexual activity to 5 Very satisfied) and Pain (3 items score range: 0 Did not attempt intercourse to 5 Almost never or never). A positive change signifies improvement. | Posted | Mean | Standard Error | units on a scale | Baseline (visit 1) average score obtained at day 1 and stable treatment period (visits 4-7) average score days 28-98 |
|
| ||||||||||||||||||||||||||||||
| Secondary | Adjusted Mean Change in Subject Bladder/Bowel Function Diary Scores | Bowel/bladder questions pertaining to the average number of times per day the patient experienced accidental urination/leakage and the average number of bowel movements per day were asked of all patients daily. A negative change in patient bladder/bowel function diary score signifies improvement. | ITT Population. Number of participants analyzed is number of patients with available data at both baseline and double-blind treatment period. | Posted | Mean | Standard Error | episodes | Baseline (visit 1) average score obtained at day 1 and double-blind treatment period (visits 4-7) average score days 28-98 |
|
| |||||||||||||||||||||||||||||
| Secondary | Adjusted Mean Change in Subject Bowel Function Diary Scores | Bowel questions pertaining to the average number of minutes per day spent on bowel routine were asked of all patients daily. A negative change in patient bowel function diary score signifies improvement. | ITT Population. Number of participants analyzed is number of patients with available data at both baseline and double-blind treatment period. | Posted | Mean | Standard Error | minutes | Baseline (visit 1) average score obtained at day 1 and double-blind treatment period (visits 4-7) average score days 28-98 |
|
|
Treatment-emergent adverse events (TEAE) include AEs with date of onset (or worsening) on or after the start of treatment and no more than 14 days after the last dose of investigational drug.
Adverse events were recorded at every study visit. Results are presented for the Safety population defined as all randomized patients who received at least one dose of study treatment.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Fampridine-SR 50mg/Day | Fampridine-SR : 25mg bid (twice daily) | 8 | 103 | 24 | 103 | ||
| EG001 | Placebo | Placebo : Placebo | 9 | 100 | 17 | 100 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Accidental Injury | Injury, poisoning and procedural complications | COSTART |
| ||
| Cellulitis | Infections and infestations | COSTART |
| ||
| Headache | Nervous system disorders | COSTART |
| ||
| Hypothermia | Infections and infestations | COSTART |
| ||
| Overdose | Psychiatric disorders | COSTART |
| ||
| Sepsis | Blood and lymphatic system disorders | COSTART |
| ||
| Atrial Fibrillation | Cardiac disorders | COSTART |
| ||
| Bradycardia | Cardiac disorders | COSTART |
| ||
| Coronary Artery Disorder | Cardiac disorders | COSTART |
| ||
| Hemorrhage | Vascular disorders | COSTART |
| ||
| Hypertension | Vascular disorders | COSTART |
| ||
| Myocardial Infarct | Cardiac disorders | COSTART |
| ||
| Intestinal Obstruction | Gastrointestinal disorders | COSTART |
| ||
| Pathological Fracture | Musculoskeletal and connective tissue disorders | COSTART |
| ||
| Tendon Disorder | Musculoskeletal and connective tissue disorders | COSTART |
| ||
| Dysautonomia | Nervous system disorders | COSTART |
| ||
| Neuropathy | Nervous system disorders | COSTART |
| ||
| Paresthesia | Nervous system disorders | COSTART |
| ||
| Somnolence | Nervous system disorders | COSTART |
| ||
| Speech Disorder | Nervous system disorders | COSTART |
| ||
| Bronchitis | Respiratory, thoracic and mediastinal disorders | COSTART |
| ||
| Pneumonia | Infections and infestations | COSTART |
| ||
| Skin Ulcer | Skin and subcutaneous tissue disorders | COSTART |
| ||
| Amblyopia | Eye disorders | COSTART |
| ||
| Urinary Tract Infection | Infections and infestations | COSTART |
|
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Hypertonia | Psychiatric disorders | COSTART |
| ||
| Urinary Tract Infection | Infections and infestations | COSTART |
| ||
| Pain | General disorders | COSTART |
| ||
| Constipation | Renal and urinary disorders | COSTART |
| ||
| Paresthesia | Nervous system disorders | COSTART |
| ||
| Insomnia | Psychiatric disorders | COSTART |
| ||
| Headache | Nervous system disorders | COSTART |
| ||
| Dizziness | Vascular disorders | COSTART |
| ||
| Infection | Infections and infestations | COSTART |
| ||
| Abdominal Pain | Gastrointestinal disorders | COSTART |
| ||
| Back Pain | Musculoskeletal and connective tissue disorders | COSTART |
| ||
| Accidental Injury | Injury, poisoning and procedural complications | COSTART |
| ||
| Nausea | Gastrointestinal disorders | COSTART |
| ||
| Peripheral Edema | General disorders | COSTART |
| ||
| Fever | General disorders | COSTART |
| ||
| Pharyngitis | Respiratory, thoracic and mediastinal disorders | COSTART |
| ||
| Flu Syndrome | Infections and infestations | COSTART |
| ||
| Migraine | Nervous system disorders | COSTART |
| ||
| Dyspepsia | Gastrointestinal disorders | COSTART |
| ||
| Ecchymosis | Vascular disorders | COSTART |
| ||
| Anxiety | Psychiatric disorders | COSTART |
| ||
| Nervousness | Psychiatric disorders | COSTART |
| ||
| Cough Increased | Respiratory, thoracic and mediastinal disorders | COSTART |
| ||
| Rash | Skin and subcutaneous tissue disorders | COSTART |
| ||
| Skin Ulcer | Skin and subcutaneous tissue disorders | COSTART |
| ||
| Sweating | Skin and subcutaneous tissue disorders | COSTART |
| ||
| Arthralgia | Musculoskeletal and connective tissue disorders | COSTART |
| ||
| Somnolence | Nervous system disorders | COSTART |
| ||
| Rhinitis | Infections and infestations | COSTART |
| ||
| Urinary Frequency | Renal and urinary disorders | COSTART |
| ||
| Urinary Incontinence | Renal and urinary disorders | COSTART |
| ||
| Asthenia | Musculoskeletal and connective tissue disorders | COSTART |
| ||
| Neck Pain | Musculoskeletal and connective tissue disorders | COSTART |
| ||
| Neck Rigidity | Musculoskeletal and connective tissue disorders | COSTART |
| ||
| Anorexia | Metabolism and nutrition disorders | COSTART |
| ||
| Gastritis | Gastrointestinal disorders | COSTART |
| ||
| Gastroenteritis | Gastrointestinal disorders | COSTART |
| ||
| Leukocvtosis | Blood and lymphatic system disorders | COSTART |
| ||
| Myalgia | Musculoskeletal and connective tissue disorders | COSTART |
| ||
| Abnormal Dreams | Psychiatric disorders | COSTART |
| ||
| Depression | Psychiatric disorders | COSTART |
| ||
| Dysautonomia | Nervous system disorders | COSTART |
| ||
| Vasodilatation | Vascular disorders | COSTART |
| ||
| Dyspnea | Cardiac disorders | COSTART |
| ||
| Cystitis | Renal and urinary disorders | COSTART |
| ||
| Hematuria | Renal and urinary disorders | COSTART |
| ||
| Urine Abnormality | Renal and urinary disorders | COSTART |
| ||
| Photosensitivity Reaction | Skin and subcutaneous tissue disorders | COSTART |
| ||
| Diarrhea | Gastrointestinal disorders | COSTART |
| ||
| Neuropathy | Nervous system disorders | COSTART |
| ||
| Sinusitis | Respiratory, thoracic and mediastinal disorders | COSTART |
| ||
| Fungal Dermatitis | Infections and infestations | COSTART |
| ||
| Amblyopia | Eye disorders | COSTART |
| ||
| Chills | General disorders | COSTART |
| ||
| Dysuria | Renal and urinary disorders | COSTART |
| ||
| Hypertension | Vascular disorders | COSTART |
| ||
| Flatulence | Gastrointestinal disorders | COSTART |
| ||
| Maculopapular Rash | Skin and subcutaneous tissue disorders | COSTART |
| ||
| Metrorrhagia | Reproductive system and breast disorders | COSTART |
|
Sponsor (Acorda) has right to review and comment on proposed publications within a specified time frame, up to 60 days; multi-center trials require joint publication unless specifically permitted otherwise.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Chief Scientific Officer | Acorda Therapeutics, Inc. | 914-347-4300 | 5102 | ablight@acorda.com |
| ID | Term |
|---|---|
| D013119 | Spinal Cord Injuries |
| D009128 | Muscle Spasticity |
| ID | Term |
|---|---|
| D013118 | Spinal Cord Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
| D020196 | Trauma, Nervous System |
| D014947 | Wounds and Injuries |
| D009135 | Muscular Diseases |
| D009140 | Musculoskeletal Diseases |
| D009122 | Muscle Hypertonia |
| D020879 | Neuromuscular Manifestations |
| D009461 | Neurologic Manifestations |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| D015761 | 4-Aminopyridine |
| ID | Term |
|---|---|
| D000631 | Aminopyridines |
| D000588 | Amines |
| D009930 | Organic Chemicals |
| D011725 | Pyridines |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
Not provided
Not provided
| Male |
|
| Black or African American |
|
| Asian/Pacific Islander |
|
| Other |
|
|
|
| Units |
|---|
| Counts |
|---|
| Participants |
|
|
|
|
|
|
|
|
|
|